Get the Stockscreener App
13.35
0.15%
0.02
After Hours:
13.30
-0.05
-0.37%
Eyepoint Pharmaceuticals Inc stock is traded at $13.35, with a volume of 648.77K.
It is up +0.15% in the last 24 hours and up +24.19% over the past month.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
See More
Previous Close:
$13.33
Open:
$13.31
24h Volume:
648.77K
Relative Volume:
0.89
Market Cap:
$920.18M
Revenue:
$46.02M
Net Income/Loss:
$-70.80M
P/E Ratio:
-7.3352
EPS:
-1.82
Net Cash Flow:
$-1.61M
1W Performance:
-4.71%
1M Performance:
+24.19%
6M Performance:
+82.13%
1Y Performance:
+50.34%
1-Day Range:
$13.21
$13.58
1-Week Range:
$13.19
$14.42
52-Week Range:
$3.91
$14.42
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
Name
Eyepoint Pharmaceuticals Inc
Sector
Industry
Phone
617-926-5000
Address
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
13.35 | 933.97M | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-25 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-22-24 | Initiated | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Mizuho | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Jul-07-22 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Jan-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Nov-04-19 | Resumed | Laidlaw | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
View All
Eyepoint Pharmaceuticals Inc Stock (EYPT) Latest News
Eyepoint Pharmaceuticals, Inc. $EYPT Shares Purchased by Invesco Ltd. - MarketBeat
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 4.4%Here's What Happened - MarketBeat
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Reaches New 1-Year HighStill a Buy? - MarketBeat
American Century Companies Inc. Acquires Shares of 42,860 Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
Walleye Capital LLC Acquires New Shares in Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
Eyepoint Pharmaceuticals, Inc. $EYPT Position Raised by Adage Capital Partners GP L.L.C. - MarketBeat
Is EyePoint Pharmaceuticals Inc. in Accumulation Phase NowJuly 2025 Setups & High Return Stock Watch Alerts - beatles.ru
Will EyePoint Pharmaceuticals Inc. stock recover after recent drop2025 Market Sentiment & Free Reliable Trade Execution Plans - Newser
Evaluating EyePoint Pharmaceuticals Inc. with trendline analysisMarket Weekly Review & Daily Growth Stock Investment Tips - Newser
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Looks Just Right With A 32% Price Jump - simplywall.st
What is the next catalyst for EyePoint Pharmaceuticals Inc.2025 Biggest Moves & Fast Moving Stock Trade Plans - خودرو بانک
Can EyePoint Pharmaceuticals Inc. outperform under higher oil pricesQuarterly Portfolio Report & Fast Gain Stock Tips - خودرو بانک
Using economic indicators to assess EyePoint Pharmaceuticals Inc. potential2025 Momentum Check & Fast Gain Stock Tips - Newser
194,897 Shares in Eyepoint Pharmaceuticals, Inc. $EYPT Purchased by Nuveen LLC - MarketBeat
What’s EyePoint Pharmaceuticals Inc.’s historical returnWeekly Investment Recap & Free Safe Entry Trade Signal Reports - خودرو بانک
What is EyePoint Pharmaceuticals Inc.’s market positionWeekly Profit Analysis & Community Verified Trade Signals - خودرو بانک
Applying Wyckoff theory to EyePoint Pharmaceuticals Inc. stockJuly 2025 PreEarnings & Precise Swing Trade Entry Alerts - Newser
What is the PEG ratio of EyePoint Pharmaceuticals Inc.July 2025 Spike Watch & Smart Investment Allocation Insights - خودرو بانک
Can EyePoint Pharmaceuticals Inc. lead its sector in growthJuly 2025 Update & Real-Time Price Movement Reports - خودرو بانک
Analyzing drawdowns of EyePoint Pharmaceuticals Inc. with statistical toolsWeekly Trading Summary & Daily Growth Stock Investment Tips - Newser
What to expect from EyePoint Pharmaceuticals Inc. in the next 30 daysQuarterly Earnings Summary & Reliable Intraday Trade Alerts - Newser
What technical models suggest about EyePoint Pharmaceuticals Inc.’s comebackWeekly Gains Report & Weekly Watchlist for Hot Stocks - Newser
Will EyePoint Pharmaceuticals Inc. see short term momentumJuly 2025 Review & Low Drawdown Trading Strategies - Newser
Technical analysis overview for EyePoint Pharmaceuticals Inc. stockJuly 2025 Update & Verified Momentum Watchlists - Newser
Eyepoint Pharmaceuticals, Inc. $EYPT Stake Boosted by Wellington Management Group LLP - MarketBeat
How to integrate EyePoint Pharmaceuticals Inc. into portfolio analysis toolsEarnings Miss & AI Driven Stock Price Forecasts - Newser
Can EyePoint Pharmaceuticals Inc. reach resistance levels soonSell Signal & Trade Opportunity Analysis - خودرو بانک
How to recover losses in EyePoint Pharmaceuticals Inc. stockBreakout Watch & Low Risk High Win Rate Picks - Newser
Multi factor analysis applied to EyePoint Pharmaceuticals Inc.July 2025 Selloffs & Verified Entry Point Detection - Newser
Volatility clustering patterns for EyePoint Pharmaceuticals Inc.Trade Risk Assessment & Long-Term Safe Return Strategies - Newser
Vanguard Group Inc. Has $20.78 Million Stock Holdings in Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
Can a trend reversal in EyePoint Pharmaceuticals Inc. lead to recoverySell Signal & Weekly Return Optimization Plans - Newser
Is now a turning point for EyePoint Pharmaceuticals Inc.Quarterly Portfolio Review & Breakout Confirmation Trade Signals - Newser
News impact scoring models applied to EyePoint Pharmaceuticals Inc.2025 Dividend Review & Free Community Consensus Stock Picks - Newser
Should I average down on EyePoint Pharmaceuticals Inc. stockInsider Selling & Verified Short-Term Trading Plans - خودرو بانک
Aug Sentiment: Why is EyePoint Pharmaceuticals Inc. stock going downJuly 2025 Summary & Consistent Return Strategy Ideas - خودرو بانک
Visual trend scoring systems applied to EyePoint Pharmaceuticals Inc.Market Sentiment Summary & Reliable Price Action Trade Plans - Newser
Real time scanner hits for EyePoint Pharmaceuticals Inc. explainedJuly 2025 Macro Moves & Capital Protection Trading Alerts - Newser
Does EyePoint Pharmaceuticals Inc. fit your quant trading model2025 Price Momentum & High Return Stock Watch Alerts - Newser
Identifying reversal signals in EyePoint Pharmaceuticals Inc.Rate Hike & Weekly High Conviction Ideas - Newser
Ranking EyePoint Pharmaceuticals Inc. among high performing stocks via tools2025 Momentum Check & Free Community Consensus Stock Picks - Newser
Best data tools to analyze EyePoint Pharmaceuticals Inc. stockPrice Action & Risk Controlled Daily Trade Plans - Newser
Is EyePoint Pharmaceuticals Inc. stock poised for growthWeekly Volume Report & Safe Capital Growth Trade Ideas - Newser
EyePoint Pharmaceuticals Inc. stock daily chart insights2025 Top Decliners & Risk Controlled Daily Plans - Newser
Why is EyePoint Pharmaceuticals Inc. stock going upMarket Performance Summary & Free Accurate Trade Setup Notifications - خودرو بانک
Eyepoint Pharmaceuticals Inc Stock (EYPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):